RNA Editing Dynamically Rewrites the Cancer Code

Violeta Rayon-Estrada¹, F Nina Papavasiliou², Dewi Harjanto²

Affiliations

¹ Laboratory of Lymphocyte Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA; The Rockefeller Graduate Program, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
² Laboratory of Lymphocyte Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.

PMID: 27695712
PMCID: PMC5042206
DOI: 10.1016/j.trecan.2015.10.008

Comment

RNA Editing Dynamically Rewrites the Cancer Code

Violeta Rayon-Estrada et al. Trends Cancer. 2015 Dec.

. 2015 Dec;1(4):211-212.

doi: 10.1016/j.trecan.2015.10.008. Epub 2015 Nov 26.

Authors

Violeta Rayon-Estrada¹, F Nina Papavasiliou², Dewi Harjanto²

Affiliations

¹ Laboratory of Lymphocyte Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA; The Rockefeller Graduate Program, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
² Laboratory of Lymphocyte Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.

PMID: 27695712
PMCID: PMC5042206
DOI: 10.1016/j.trecan.2015.10.008

Abstract

Global analyses of cancer transcriptomes demonstrate that ADAR (adenosine deaminase, RNA-specific)-mediated RNA editing dynamically contributes to genetic alterations in cancer, and directly correlates with progression and prognosis. RNA editing is abundant and frequently elevated in cancer, and affects functionally and clinically relevant sites in both coding and non-coding regions of the transcriptome. Therefore, ADAR and differentially edited transcripts may be promising biomarkers or targets for therapy.

PubMed Disclaimer

Figures

**Figure 1**
Adding RNA Editing to Current Paradigms of Cancer Progression. (A) Cancer model of DNA mutation, selection, and adaptation. (B) RNA editing contribution to selection and adaptation. Abbreviations: ADAR, adenosine deaminase, RNA-specific; APOBEC1, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 1.

See this image and copyright information in PMC

Comment on

The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.
Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HMJ, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LWT, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. Han L, et al. Cancer Cell. 2015 Oct 12;28(4):515-528. doi: 10.1016/j.ccell.2015.08.013. Epub 2015 Oct 1. Cancer Cell. 2015. PMID: 26439496 Free PMC article.
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.
Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V. Fumagalli D, et al. Cell Rep. 2015 Oct 13;13(2):277-89. doi: 10.1016/j.celrep.2015.09.032. Epub 2015 Oct 1. Cell Rep. 2015. PMID: 26440892 Free PMC article.
Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors.
Paz-Yaacov N, Bazak L, Buchumenski I, Porath HT, Danan-Gotthold M, Knisbacher BA, Eisenberg E, Levanon EY. Paz-Yaacov N, et al. Cell Rep. 2015 Oct 13;13(2):267-76. doi: 10.1016/j.celrep.2015.08.080. Epub 2015 Oct 1. Cell Rep. 2015. PMID: 26440895

References

1. Fumagalli D. Principles governing A-to-I RNA editing in the breast cancer transcriptome. Cell Rep. 2015;13:277–289. - PMC - PubMed
1. Han L, et al. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell. 2015;28:515–528. - PMC - PubMed
1. Paz-Yaacov N, et al. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 2015;13:267–276. - PubMed
1. Bazak L, et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014;24:365–376. - PMC - PubMed
1. Fitzgerald LW, et al. Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacol. 1999;21:82S–90S. http://www.ncbi.nlm.nih.gov/pubmed/10432493. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

RNA Editing Dynamically Rewrites the Cancer Code

Affiliations

RNA Editing Dynamically Rewrites the Cancer Code

Authors

Affiliations

Abstract

Figures

Comment on

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials